Tislelizumab-jsgr
TEVIMBRA (tislelizumab-jsgr) is an intravenous injection used as an immunotherapy drug that blocks programmed death receptor-1 (PD-1) to help the immune system fight certain cancers. Manufactured by BeOne Medicines USA, Inc., it's available as a 10 mg/mL solution concentrate, approved under BLA761232 and marketed since March 2024. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | TEVIMBRA (tislelizumab-jsgr) is an intravenous injection used as an immunotherapy drug that blocks programmed death receptor-1 (PD-1) to help the immune system fight certain cancers. Manufactured by BeOne Medicines USA, Inc., it's available as a 10 mg/mL solution concentrate, approved under BLA761232 and marketed since March 2024. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Tislelizumab-jsgr",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Tislelizumab-jsgr — ANDA 761232 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761232"
}
]
|
| identifier | ANDA761232 |
| issued | 2016-09-16 |
| keyword |
[
"drug-information",
"drug-manufacturers",
"drug-safety",
"prescription-drugs",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Tislelizumab-jsgr |
